Using Tissue Cell Culture To Make A Protein Or Polypeptide Patents (Class 435/70.1)
-
Patent number: 8541204Abstract: The current invention describes a nucleic acid comprising in a 5? to 3? direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5? splice donor site and terminated by a 3? splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.Type: GrantFiled: December 5, 2012Date of Patent: September 24, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Josef Endl, Erhard Kopetzki, Oliver Ploettner, Ursula Schwarz, Georg Tiefenthaler
-
Patent number: 8541003Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.Type: GrantFiled: June 21, 2004Date of Patent: September 24, 2013Assignee: Protein Sciences CorporationInventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
-
Patent number: 8535930Abstract: The invention relates to a method of producing a HPV polypeptides and/or an influenza virus H5 polypeptide in a plant comprising the steps of cloning a HPV gene; and/or an influenza virus H5 gene or nucleic acid encoding their functional equivalents into a vector adapted to target components present in the plant, infiltrating at least a portion of the plant with the vector or transforming plant tissue with the vector so as to transiently express the HPV polypeptides and/or an influenza virus H5 polypeptide, and/or to create a transgenic plant; and recovering the HPV polypeptides and/or an influenza virus H5 polypeptide expressed by the plant. The invention further relates to vectors, transgenic plants or parts thereof and the progeny of such plants used in or which come about as a result of the method.Type: GrantFiled: May 2, 2006Date of Patent: September 17, 2013Assignee: University of Cape TownInventors: Anna-Lise Williamson, Edward Peter Rybicki, James Malcolm MacLean, Inga Isabel Becker-Hitzeroth
-
Publication number: 20130236924Abstract: Multi-well plate (1) comprising a plurality of wells (4), a frame (5) for holding the plurality of wells (4) in a defined arrangement, a support element (50) for contacting a surface when the multi-well plate (1) is placed on the surface, wherein at least one well (4) of the plurality of wells is elastically displaceable relative to said support element (50).Type: ApplicationFiled: July 27, 2011Publication date: September 12, 2013Applicant: INSPHERO AGInventors: Jan Lichtenberg, Wolfgang Moritz, Jens Kelm
-
Patent number: 8530233Abstract: The present invention provides a novel expression vector which comprises a gene of interest, a nuclear anchoring element, and at least one inverted repeat element, preferably two inverted repeat elements. The expression vector is an episomal vector capable of transfecting a mammalian cell. The present invention further provides a method for enhancing gene expression by transfecting the expression vector to a mammalian cell, preferably a human cell.Type: GrantFiled: October 2, 2007Date of Patent: September 10, 2013Assignee: Genetai IncInventor: Ching-Tai Lin
-
Patent number: 8524875Abstract: DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.Type: GrantFiled: December 22, 2009Date of Patent: September 3, 2013Assignee: California Institute of TechnologyInventors: Tatjana Sauka-Spengler, Sonja J. McKeown, Paola Betancur, Marianne Bronner
-
Patent number: 8524221Abstract: Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.Type: GrantFiled: May 5, 2011Date of Patent: September 3, 2013Assignee: Sangamo BioSciences, Inc.Inventors: Dale Ando, Michael C. Holmes, Yann Jouvenot, Gary Ka Leong Lee
-
Patent number: 8518695Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.Type: GrantFiled: January 11, 2012Date of Patent: August 27, 2013Assignees: Novartis AG, Universite de StrasbourgInventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
-
Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
Patent number: 8512981Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.Type: GrantFiled: June 20, 2007Date of Patent: August 20, 2013Assignee: Amsterdam Molecular Therapeutics B.V.Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker -
Patent number: 8513391Abstract: Described herein are a number of Ebola and Marburg monoclonal antibodies.Type: GrantFiled: January 27, 2009Date of Patent: August 20, 2013Inventors: Steven Jones, Xiangguo Qiu, Heinz Feldmann, Ute Stroeher
-
Patent number: 8513018Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: May 29, 2012Date of Patent: August 20, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8507238Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: October 8, 2012Date of Patent: August 13, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8507267Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: GrantFiled: March 8, 2010Date of Patent: August 13, 2013Assignee: U.S. Dept. of Health and Human Services, National Institutes of HealthInventors: John A. Chiorini, Robert M. Kotin, Nancy Safer
-
Patent number: 8507222Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: GrantFiled: September 21, 2011Date of Patent: August 13, 2013Assignee: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 8501464Abstract: It is described a bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells; bidirectional expression cassettes; expression constructs; gene transfer expression vectors, and methods for the use thereof.Type: GrantFiled: April 21, 2004Date of Patent: August 6, 2013Assignee: Ospedale San Raffaele S.r.l.Inventors: Luigi Naldini, Mario Amendola, Elisa Vigna
-
Patent number: 8501914Abstract: A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.Type: GrantFiled: August 13, 2009Date of Patent: August 6, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Yutaka Kanda, Hiroshi Sato, Tsuyoshi Yamada, Akifumi Kato, Mitsuo Satoh
-
Patent number: 8497355Abstract: A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.Type: GrantFiled: September 26, 2008Date of Patent: July 30, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Taichi Kuramochi, Hirotake Shiraiwa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Takahiro Ishiguro
-
Patent number: 8492116Abstract: [PROBLEMS] To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc. [MEANS FOR SOLVING PROBLEMS] A novel soluble polypeptide protein.Type: GrantFiled: October 21, 2004Date of Patent: July 23, 2013Assignee: Teijin Pharma LimitedInventors: Kei Yamana, Yasunori Nakayama, Yoshimasa Takahashi, Eiji Ochiai, Hitoshi Wada, Yoshiaki Azuma
-
Patent number: 8475806Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes a sequence from a high titer influenza virus isolate.Type: GrantFiled: May 27, 2004Date of Patent: July 2, 2013Assignee: Wisconsin Alumni Research FoundationInventor: Yoshihiro Kawaoka
-
Patent number: 8470581Abstract: The present invention provides methods for increasing the amount of isoprene produced by cultured cells with only a minimal increase in carbon dioxide emitted, thereby resulting in process having a greater yield of isoprene relative to carbon dioxide. In addition, the present invention provides compositions that include the cultured cells or isoprene produced there from.Type: GrantFiled: September 15, 2009Date of Patent: June 25, 2013Assignees: Danisco US Inc., The Goodyear Tire & Rubber CompanyInventors: Gopal K. Chotani, Alex Nielsen, Karl J. Sanford
-
Patent number: 8470993Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 22, 2012Date of Patent: June 25, 2013Assignees: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 8470562Abstract: A highly efficient method of making a primary cell derived biologic by purifying mononuclear cells (MNCs) in a automated cell processor to remove contaminating cells by loading leukocytes onto lymphocyte separation medium (LSM) and centrifuging the medium to obtain purified MNCs, storing the MNCs overnight in a closed sterile bag system, stimulating an induction mixture of the MNCs with phytohemagglutinin (PHA) or other mitogen and ciprofloxacin in a scalable cell culture device and producing a primary cell derived biologic from the MNCs, removing the mitogen from the induction mixture by filtering, incubating the induction mixture, clarifying the induction mixture by filtering to obtain a primary cell derived biologic supernatant, and clearing the primary cell derived biologic supernatant from adventitious agents by anion exchange chromatography, filtration. A closed system prevents contamination of the resulting primary cell derived biologic. An automated method of purifying cells.Type: GrantFiled: April 14, 2009Date of Patent: June 25, 2013Assignee: IRX Therapeutics, Inc.Inventors: George J. Fennington, Jr., Harvey J. Brandwein
-
Patent number: 8466271Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: GrantFiled: July 22, 2009Date of Patent: June 18, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co, KGInventor: Barbara Enenkel
-
Patent number: 8465948Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.Type: GrantFiled: July 28, 2011Date of Patent: June 18, 2013Assignee: Prolor Biotech Ltd.Inventors: Fuad Fares, Udi Eyal Fima
-
Patent number: 8461421Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:61-121 and 133-141, or the nucleotide sequence set forth in SEQ ID NO:1-60, 124-132, and 142-283, as well as variants and fragments thereof.Type: GrantFiled: June 25, 2009Date of Patent: June 11, 2013Assignee: Athenix Corp.Inventors: Kimberly S. Sampson, Daniel John Tomso, Shruti Agarwal, Brian McNulty, Chris Campbell
-
Patent number: 8455628Abstract: The invention relates to phosphatase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PP1 activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.Type: GrantFiled: May 2, 2008Date of Patent: June 4, 2013Assignee: Intrexon CorporationInventors: Thomas Reed, Amy Atzel, David Bachinsky, Anna Tretiakova
-
Patent number: 8445235Abstract: The current invention pertains to a method to produce RTX-toxins ApxI or ApxIII by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, characterized in that air is passed through the medium, wherein the air has a carbon dioxide content above normal atmospheric level to increase RTX-toxin production during the production phase of the RTX-toxins.Type: GrantFiled: November 25, 2009Date of Patent: May 21, 2013Assignee: Intervet International B.V.Inventors: Simen-Jan Slagman, Christian Theodoor Gerardus Smits
-
Publication number: 20130122040Abstract: The present invention relates to a fermentation medium for cultivating Corynebacterium diphtheriae. The present invention also relates to the use of the fermentation medium in processes for obtaining diphtheria toxin from the Corynebacterium diphtheriae bacteria being cultivated and the preparation of vaccines using the diphtheria toxin obtained in the processes. The present invention further relates to a purification and detoxification processes specifically adapted for preparing a diphtheria toxoid for inclusion into a vaccine.Type: ApplicationFiled: November 9, 2012Publication date: May 16, 2013Applicant: NOVARTIS AGInventor: Novaritis AG
-
Publication number: 20130115279Abstract: An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.Type: ApplicationFiled: January 9, 2013Publication date: May 9, 2013Applicant: IMMUNOCELLULAR THERAPEUTICS, LTD.Inventor: IMMUNOCELLULAR THERAPEUTICS, LTD.
-
Patent number: 8435535Abstract: The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.Type: GrantFiled: February 14, 2012Date of Patent: May 7, 2013Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Eva Felder
-
Patent number: 8431383Abstract: High yield antibiotics producing fungus strain, preparation method and use thereof are provided. The fungus strain is a mutant derived from Glarea lozoyensis, and deposited in CGMCC with the accession number of CGMCC 2933. The preparation method concludes following steps: (a) mixing the culture media of Glarea lozoyensis strain ATCC 20957 with nitrosoguanidine, and obtaining mixture a; (b) mixing lywallzyme with the mixture a, and obtaining protoplasts; (c) regenerating the protoplasts, and obtaining single clones; and (d) culturing the single clones, then obtaining the mutant strain. This fungus strain has stable genetic and producing property, produces little impurities in fermentation, and is suitable to be used in industry.Type: GrantFiled: September 28, 2009Date of Patent: April 30, 2013Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Jing Xu, Yi Chen, Xiaoming Ji, Xiaoliang Gao, Shidong Liu, Zhaoli Zhang
-
Patent number: 8426573Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: March 7, 2012Date of Patent: April 23, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
-
Patent number: 8426167Abstract: The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria, such as Escherichia coli. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkpA, SlyD, and trigger factor; methods of recombinant protein expression, the recombinant polypeptides thus obtained, as well as to the use of such polypeptides.Type: GrantFiled: April 13, 2007Date of Patent: April 23, 2013Assignee: Roche Diagnostics Operations, Inc.Inventors: Christian Scholz, Herbert Andres, Elke Faatz, Alfred Engel, Urban Schmitt, Ariuna Bazarsuren, Peter Schaarschmidt
-
Patent number: 8426124Abstract: The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained.Type: GrantFiled: April 30, 2008Date of Patent: April 23, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt
-
Patent number: 8426202Abstract: The invention relates to nutrient media, in particular cell culture media, which contain at least one substance selected from the group comprising citric acid, succinic acid, malic acid, ?-keto-glutaric acid, fumaric acid, oxalacetic acid, isocitric acid, oxalosuccinic acid, tartaric acid, lactic acid, adipic acid and mixtures thereof and salts, derivatives or complexes of these acids. The invention further relates to the use and methods of production of said cell culture media, methods of cultivation of a cell culture in a cell culture medium according to the invention and cells that can be obtained by said methods.Type: GrantFiled: September 8, 2006Date of Patent: April 23, 2013Assignee: Cellca GmbHInventor: Aziz Cayli
-
Publication number: 20130096028Abstract: The present invention relates to a mouse epithelial cell line constantly producing TSLP and use thereof. More specifically, the present invention relates to a method for screening for a TSLP modulator using a mouse epithelial cell line (KCHM-1) constantly producing TSLP, and a method for producing wild-type TSLP using the cell line.Type: ApplicationFiled: June 13, 2011Publication date: April 18, 2013Applicant: TOHOKU UNIVERSITYInventors: Noriyasu Hirasawa, Michihiro Hide
-
IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS
Publication number: 20130084243Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.Type: ApplicationFiled: November 29, 2012Publication date: April 4, 2013Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Patent number: 8404233Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.Type: GrantFiled: May 15, 2008Date of Patent: March 26, 2013Assignee: Smart Targeting LimitedInventors: Makoto Sunamura, Hideo Yagita
-
Patent number: 8399648Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: April 13, 2012Date of Patent: March 19, 2013Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8399220Abstract: The present invention relates to oral antibacterial compositions comprising trihydroxybenzoate derivatives, e.g., useful for the treatment of gum diseases (e.g., gingivitis or periodontitis) and to methods of using such compositions.Type: GrantFiled: April 16, 2010Date of Patent: March 19, 2013Assignee: Forsyth Dental Infirmary for ChildrenInventors: Toshihisa Kawai, Philip P. Stashenko, Yoshiaka Hosokawa, Kazuhisa Ohara
-
Publication number: 20130065254Abstract: This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: VICTORIA V. LUNYAK
-
Publication number: 20130059006Abstract: A bioscaffold made from an isolated cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) is disclosed. The bioscaffold can be used as an epicardial patch for the delivery of therapeutic cells into myocardial tissue. Methods of making the 3-dimensional extracellular matrix using cultured cardiac fibroblasts are also disclosed.Type: ApplicationFiled: August 24, 2012Publication date: March 7, 2013Applicant: Wisconsin Alumni Research FoundationInventors: Eric G. Schmuck, Kurt W. Saupe
-
Publication number: 20130059339Abstract: A bioreactor (1) for the culture of cells (C) comprising a stack of carriers (7) for cell (C) adherence and liquid medium (M) distribution. The carriers (7) are stacked so as to define levels (6) between adjacent carriers (7) for the flow of the liquid medium (M). Adjacent levels (6) are fluidly interconnected via open spaces (2) so that the liquid medium (M) can flow from one level (6) to an adjacent level (6). The open spaces (2) between a first and an adjacent second level (6?) do not overlap with the one or more open spaces (2) between the second level (6?) and an adjacent third level (6?). One or more of the carriers may also include an area adapted to prevent cell adhesion or growth, thereby allowing for the viewing of cell growth on adjacent carriers from a vantage point external to the bioreactor. Related methods are also disclosed.Type: ApplicationFiled: May 11, 2011Publication date: March 7, 2013Inventors: Didier Karerangabo, Julien Cardon, Jose Antonio Castillo Gonzalez
-
Patent number: 8389238Abstract: Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3?BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3? BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.Type: GrantFiled: September 12, 2008Date of Patent: March 5, 2013Assignee: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Linas Padegimas
-
Patent number: 8389704Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: GrantFiled: February 15, 2008Date of Patent: March 5, 2013Assignee: MedImmune LimitedInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Patent number: 8383365Abstract: Modified FGF-21 polypeptides and uses thereof are provided.Type: GrantFiled: March 18, 2011Date of Patent: February 26, 2013Assignee: AMBRX, Inc.Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore (Nee Ho), Jason Pinkstaff, Vadim Kraynov
-
Patent number: 8377689Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.Type: GrantFiled: September 24, 2010Date of Patent: February 19, 2013Assignee: ReNeuron, Inc.Inventors: Wen-Ghih Tsang, Yanping Wang, Jinghua Tang
-
Patent number: 8372603Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: GrantFiled: March 7, 2012Date of Patent: February 12, 2013Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Zhengxing Qu, Chien-Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Nordstrom
-
Patent number: 8367319Abstract: Compositions and methods are provided to identify functional mutant ribosomes that may be used as drug targets. The compositions and methods allow isolation and analysis of mutations that would normally be lethal and allow direct selection of rRNA mutants with predetermined levels of ribosome function. The compositions and methods of the present invention may be used to identify antibiotics to treat a large number of human pathogens through the use of genetically engineered rRNA genes from a variety of species. The invention further provides novel plasmid constructs to be used in the methods of the invention.Type: GrantFiled: April 30, 2010Date of Patent: February 5, 2013Assignee: Wayne State UniversityInventor: Phillip R. Cunningham
-
Patent number: 8367374Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: January 22, 2004Date of Patent: February 5, 2013Assignee: Roche GlycArt AGInventors: Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter